Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Ultragenyx Pharmaceutical Inc. (RARE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
51.57+0.32 (+0.62%)
At close: 04:00PM EDT
51.57 0.00 (0.00%)
After hours: 04:00PM EDT
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    NOVATO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of non-qualified stock options to purchase an aggregate of 27,500 shares of common stock of the company and 14,500 restricted stock units of the company’s common stock to two newly hired non-executive officers of the company. The awards were approv

  • Zacks

    Ultragenyx's (RARE) Q2 Earnings Miss Estimates, Revenues Up

    Ultragenyx (RARE) reports a wider-than-expected loss in the second quarter. Nevertheless, revenues marginally beat estimates.

  • Benzinga

    Ultragenyx Pharma Posts Smaller Than Expected Q2 Loss, Reaffirms Guidance

    Ultragenyx Pharmaceutical Inc's (NASDAQ: RARE) Q2 sales reached $89.3 million, up from $86.97 million a year ago, beating the consensus of $87.51 million. The company recognized $64.0 million in Crysvita (burosumab) revenue in the Ultragenyx territories, including $51.6 million in collaboration revenue in the North American profit share territory and net product sales in other territories regions of $12.4 million. Yoyalty revenue related to European Crysvita sales was $5.4 million. Dojolvi's (tr

Advertisement
Advertisement